SINGAPORE, Dec. 08, 2025 — (NASDAQ: GDTC) CytoMed Therapeutics (“CytoMed” or the “Company”), a Singapore-based clinical-stage biopharmaceutical firm dedicated to creating novel, affordable donor-derived cell immunotherapies for a wide spectrum of cancers, today announced it has signed a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”). This partnership aims to establish a multi-site, first-in-human Phase I clinical trial in Malaysia to evaluate the safety and efficacy of CytoMed’s patented allogeneic, unmodified Gamma Delta (γδ) T cells (“CTM-GDT”) for cancer patients with limited treatment options.
This new trial complements CytoMed’s ongoing first-in-human Phase I CAR-T clinical trial in Singapore, which utilizes γδ T cells engineered with a proprietary chimeric antigen receptor (“CTM-N2D”) to target various cancers.
CytoMed’s Chairman, Peter Choo, stated: “Our collaboration with UMMC will help provide an affordable immunotherapy alternative for patients with few other options, leveraging the natural cancer-fighting ability of T cells. Unlike most current autologous therapies made from a patient’s own cells, CytoMed’s allogeneic technology manufactures highly pure γδ T cells from healthy donors, which do not cause immune rejection. This approach is more cost-effective and logistically simpler, enhancing accessibility for patients locally and abroad.”
The potential of unmodified γδ T cells to eliminate cancer cells has been shown in global clinical trials. CytoMed co-authored a research article in September 2025, resulting from a collaboration with The University of Texas MD Anderson Cancer Center (“MDACC”), which indicates strong promise for CTM-GDT in treating acute myeloid leukemia. This work falls under a research agreement announced in May 2023, and the article is freely available online.
“These promising results justify further clinical investigation of allogeneic γδ T cells for cancer. They will help us progress our unmodified γδ T cell therapy into clinical trials in Southeast Asia, offering new options for patients in need,” added Peter Choo.
Professor Dr. Lim Soo Kun, Head of the Clinical Investigation Centre at UMMC, said: “UMMC is committed to broadening access to promising, evidence-based treatments for Malaysian patients. We are excited to partner with CytoMed on this groundbreaking first-in-human trial to explore donor-derived γδ T cells as a viable immunotherapy for cancers with few alternatives. This alliance underscores our joint dedication to advancing clinical innovation for our community.”
About CytoMed Therapeutics Limited (CytoMed)
Founded in 2018 as a spin-off from Singapore’s Agency for Science, Technology and Research (A*STAR), CytoMed is a clinical-stage biopharmaceutical company. It leverages its licensed proprietary platforms, including gamma delta T cell and iPSC-derived gamma delta Natural Killer T cell technologies, to develop novel allogeneic cell immunotherapies for cancer. The company’s innovation is driven by the success of CAR-T therapies in blood cancers and the challenges of applying this approach to solid tumors.
Forward Looking Statements
This press release includes forward-looking statements under the Private Securities Litigation Reform Act of 1995. These statements relate to plans, objectives, expectations, and future performance, and are identified by words like “may,” “will,” “expect,” and “anticipate.” Such statements are not guarantees and involve risks and uncertainties that could cause actual results to differ materially. Risks include the development and commercialization of product candidates, the progress of clinical trials, financial estimates, and the ability to secure partnerships or funding. Investors are advised not to rely unduly on these forward-looking statements. Further details on risks are available in the Company’s SEC filings at www.sec.gov. The Company disclaims any obligation to update these statements after the date of this release.
Contact:
CytoMed Therapeutics Limited
enquiry@cytomed.sg
Attention : Evelyn Tan, Chief Corporate Officer
